Literature DB >> 27405065

C1 Inhibitor Limits Organ Injury and Prolongs Survival in Swine Subjected to Battlefield Simulated Injury.

James C Campbell1, Yansong Li, Edwin van Amersfoort, Anurag Relan, Michael Dubick, Forest Sheppard, Anthony Pusateri, Debra Niemeyer, George C Tsokos, Jurandir J Dalle Lucca.   

Abstract

Complement system activation is recognized as a deleterious component of the mammalian physiological response to traumatic injury with severe hemorrhage (TH). Female Yorkshire swine were subjected to a simulated austere prehospital battlefield scenario. Each animal underwent controlled hemorrhage of 22 mL/kg at 100 mL/min rate for approximately 10 min followed by soft tissue injury, femur fracture, and spleen injury. Subsequent blood loss was uncontrolled. Twenty-eight minutes postinjury the animals were randomized into treatment or no treatment with recombinant human C1 esterase inhibitor (C1INH) (500 IU/kg, n = 11) and into receiving or not permissive hypotensive resuscitation (n = 14) with infusion of 45 mL/kg lactated Ringer's solution (2× blood lost). Observation and animal maintenance continued for 6 h at which time the animals had either expired or were euthanized. Heart, lung, and small intestine tissue samples were collected. Pharmacokinetic, hemodynamic, and metabolic parameters as well as survival time, plasma complement activity and tissue deposition, cytokine levels, and tissue injury were determined. We found that administration of C1INH protected tissues from damage, reduced the levels of inflammatory cytokines, and improved blood chemistry. Immunohistochemical analyses revealed that C1INH administration following TH markedly reduced complement activation and deposition in tissues. Importantly, C1INH administration prolonged survival of animals particularly in those which received resuscitation fluid infusion. Our data urge early administration of C1INH to limit organ damage and prolong survival of those injured in the battlefield.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27405065     DOI: 10.1097/SHK.0000000000000677

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  5 in total

1.  Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock.

Authors:  Martijn van Griensven; Daniel Ricklin; Stephanie Denk; Rebecca Halbgebauer; Christian K Braun; Anke Schultze; Felix Hönes; Sofia Koutsogiannaki; Alexandra Primikyri; Edimara Reis; David Messerer; Sebastian Hafner; Peter Radermacher; Ali-Reza Biglarnia; Ranillo R G Resuello; Joel V Tuplano; Benjamin Mayer; Kristina Nilsson; Bo Nilsson; John D Lambris; Markus Huber-Lang
Journal:  Shock       Date:  2019-01       Impact factor: 3.454

Review 2.  Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction.

Authors:  Ebru Karasu; Bo Nilsson; Jörg Köhl; John D Lambris; Markus Huber-Lang
Journal:  Front Immunol       Date:  2019-03-21       Impact factor: 7.561

3.  Indices of complement activation and coagulation changes in trauma patients.

Authors:  Zhangsheng Yang; Milomir O Simovic; Bin Liu; Matthew B Burgess; Andrew P Cap; Jurandir J DalleLucca; Yansong Li
Journal:  Trauma Surg Acute Care Open       Date:  2022-09-14

4.  Early complementopathy predicts the outcomes of patients with trauma.

Authors:  Yansong Li; Qingwei Zhao; Bin Liu; Alexander Dixon; Leopoldo Cancio; Michael Dubick; Jurandir Dalle Lucca
Journal:  Trauma Surg Acute Care Open       Date:  2019-04-11

5.  HMGB1 Inhibition to Ameliorate Organ Failure and Increase Survival in Trauma.

Authors:  Zhangsheng Yang; Milomir O Simovic; Peter R Edsall; Bin Liu; Tomas S Cancio; Andriy I Batchinsky; Leopoldo C Cancio; Yansong Li
Journal:  Biomolecules       Date:  2022-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.